Vogalib (metopimazine) is an antiemetic, a therapeutic domain used in situations involving certain distressing symptoms, primarily nausea and vomiting. This medication helps address symptoms related to heightened physiological activity, offering supportive relief during acute episodes. It is commonly applied for patient groups including adults and children who are over six years of age when supportive symptom management is appropriate.

The medication is commonly used across conditions presenting with acute manifestations of sickness, including those associated with travel sickness (kinetosis) and symptomatic episodes not linked to fever, as well as for some forms of chemotherapy-related sickness. The therapeutic intent is focused on managing the intensity of these symptoms. “The choice of formulation assists with maintaining functional stability and may assist with providing supportive relief when symptoms interfere with routine activities.” It is applied in scenarios where additional management of discomfort is required, contributing to easing the overall symptom load during episodes of heightened distress.

---

Quick Fact: Relief for Acute Queasiness and Vomiting

Regulatory References

1. French National Agency for the Safety of Medicines and Health Products (ANSM) Summary of Product Characteristics

Eligibility for Vogalib (Metopimazine)

The use of Vogalib is defined by specific population eligibility rules documented in official regulatory labeling. It is approved for use in adults and children over 6 years of age for the orodispersible tablet form.

Contraindications: Who Must Not Use Vogalib

The medicine is strictly contraindicated for patients with a known hypersensitivity to metopimazine and in individuals with a risk of closed-angle glaucoma or urinary retention related to prostate problems. Due to the excipient aspartame, it is also contraindicated for patients with phenylketonuria.

Restricted and Conditional Use

Use requires caution in certain populations. This includes the elderly and patients with severe liver disease or severe kidney disease due to the potential for drug accumulation. The orodispersible tablet is not recommended for children under 6 years of age, though an alternative liquid formulation may be used under specific circumstances. For pregnant and breastfeeding women, use is generally not recommended or requires specific medical caution.

Interactions with other medicines and products

The interaction profile for Vogalib (Metopimazine) is classified based on its pharmacological properties and absorption characteristics, as documented in official regulatory sources.

---

Pharmacodynamic Interactions and Restrictions

Co-administration with Dopaminergic Agonists (e.g., Levodopa) is officially contraindicated. This restriction is due to pharmacodynamic antagonism, where Metopimazine's action directly cancels the therapeutic effect of the agonist, particularly relevant in Parkinson's disease. Significant pharmacodynamic reinforcement is documented when Vogalib is combined with Central Nervous System (CNS) Depressants, including Alcohol, Opioid Analgesics, and Sedatives. This combination results in an increased additive risk of drowsiness and generalized sedation. The profile also notes potential mutual antagonism with Anticholinergic Drugs concerning digestive tract motility, and an increased risk of orthostatic hypotension when combined with Antihypertensive Agents.

---

Pharmacokinetic and Administration Timing

A critical pharmacokinetic constraint involves Food. Administration of Metopimazine with a meal formally reduces its oral absorption, which subsequently leads to a documented decrease in systemic drug exposure ( AUC and C max). This interaction necessitates a mandatory timing rule requiring administration separation from food to ensure adequate bioavailability. Regarding metabolism, Metopimazine is primarily processed by a liver amidase, resulting in a low risk of clinically significant interaction with the Cytochrome P450 enzyme system.

How Vogalib Works

Vogalib (Metopimazine) acts as a competitive antagonist of Dopamine D2 receptors ( D2R), exerting both central and peripheral pharmacodynamic effects. The primary mechanism involves action at the Chemoreceptor Trigger Zone (CTZ), a region outside the blood-brain barrier. By occupying the D2 binding sites, the drug prevents activation by dopamine, thereby interfering with afferent neurological signaling that targets the central vomiting center (Nucleus Tractus Solitarius). This antagonism results in the reduction of signal transmission originating from the CTZ.

A secondary action occurs in the gastrointestinal (GI) system. D2 receptor antagonism within the GI tract modulates neural and muscular control. This influence on the peripheral system decreases hyperperistalsis and excessive muscle tone in the stomach and upper bowel, resulting in localized modulation of GI motility.

Instruction Map: How to use Vogalib — Standard Administration Guidelines

This section details the procedural constraints and rules for administering the antiemetic Metopimazine (Vogalib).

Administration Scope

Parameter	Instruction
Route of administration	Oral via the orodispersible tablet.
Dosing schedule (Adults)	Standard Dose: One 7.5 mg lyophilisate at symptom onset. The total daily dose must not exceed 30 mg (four units).
Timing in relation to meals	Take preferably 15 minutes before meals (preprandially).
Preparation requirements	Place on the tongue to disintegrate, or dissolve in half a glass of water. The tablet must not be chewed.
Age-group administration rules	Approved for children over 6 years of age. The maximum daily dose for this population is 15 mg (two units). Children under 6 years require the oral solution formulation.
Special procedural conditions	Treatment duration should not exceed 2 consecutive days. A minimum interval of 4 to 6 hours must be respected between administrations.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Oral (orodispersible or dissolved).
Frequency pattern	As-needed (at onset of symptoms), constrained to a maximum of four times daily.
Use-context constraints	Short-term use (maximum 2 days); restricted daily total dose; mandatory interval between doses; preprandial timing.

---

Resulting Procedural Structure

Step sequence:

• The 7.5 mg dose is taken orally 15 minutes before a meal.
• Dosing repetition is limited by a 4- to 6-hour minimum interval.
• The total daily intake must adhere to the maximum limits (30 mg adult / 15 mg pediatric).

Connection to the overall use protocol: The provided instructions establish a defined oral, as-needed, short-course regimen constrained by clear maximum daily doses and frequency intervals. These boundaries limit the use of the 7.5 mg formulation to a brief period of no more than two days and specify the necessary pre-meal timing for standardized use.

Research Evidence / Overview of Studies for Vogalib (Metopimazine)

---

Evidence for Use in Acute, Symptomatic Nausea and Vomiting

Research has explored the clinical evaluation of metopimazine for use in general, acute episodes of nausea and vomiting, and the evidence base is derived from several sources, including both older, controlled clinical trials and extensive historical clinical use data. These trials and data were applied in studies examining patient-reported experiences when individuals experience conditions associated with acute or disruptive episodes.

Researchers examined outcomes related to physical discomfort. Findings from some of the earlier controlled trials reported measurements of symptom patterns when metopimazine was compared to a placebo in studies of acute vomiting. This evidence contributes to the understanding of the research landscape in this context. The evidence is limited for recent, large-scale, placebo-controlled trials specifically examining its short-term use in common, non-severe vomiting episodes.

---

Evidence for Use in Chemotherapy-Induced Symptoms (CINV)

Metopimazine was studied in research settings exploring nausea and vomiting linked to certain cancer treatments. This research often involved Randomized Controlled Trials (RCTs), where metopimazine was evaluated in comparison to other active antiemetics or a placebo. The studies explored the drug's use both as a single agent and, more frequently, as an adjunct treatment to other antiemetic protocols.

Key outcomes examined included the achievement of a Complete Response, defined as no vomiting and no need for rescue medication. Findings reported patterns where the addition of metopimazine to an existing regimen was associated with the proportion of patients whose outcomes met the Complete Response definition in some studies. There is limited information for its use as a stand-alone treatment for forms of chemotherapy-related sickness involving higher symptom burdens.

---

What is Still Uncertain About Vogalib's Research Base

The current evidence describes what has been observed so far, but it also highlights certain areas where research is still ongoing. The research available focuses predominantly on short-term symptom changes related to acute or episodic manifestations. Consequently, there is limited information for long-term outcomes or the effects of extended use of the medicine, as follow-up durations were typically limited to the acute period of symptom risk.

Key Studies & References VOGALIB 7.5MG nausea vomiting LYOPHILISAT (ANSM/French Regulator related information on short-term use/indications)

Common questions about Vogalib (FAQ)

---

Q: Can I take Vogalib if I have a pre-existing heart condition?

Official information indicates that caution is advised for patients who have risk factors for Torsade de Pointes, which is a specific type of abnormal heart rhythm. Uncommon adverse effects noted in the official product information include tachycardia (a fast heartbeat) and orthostatic hypotension (a drop in blood pressure when standing). Patients who have pre-existing heart conditions should consult their healthcare professional to determine if this medicine is appropriate for their use.

---

Q: If I miss a dose of Vogalib, should I double the next dose?

Regulatory documents state that a double dose must not be taken to compensate for a forgotten dose. The constraints related to the maximum daily intake and the required minimum time interval between doses are established to control the use of the medicine.

---

Q: What should I do if my symptoms of nausea are not better after taking Vogalib for two days?

The official instructions establish that the maximum recommended duration of treatment is two consecutive days. If symptoms persist or fail to improve after this maximum treatment period, patients should seek guidance from a healthcare professional.

---

Q: Is it safe for me to drive or operate machinery after taking this medicine?

Official safety information notes that drowsiness (somnolence) is classified as a common adverse effect of this medicine. Because drowsiness can affect a person’s attention and reaction time, this potential effect may impair the ability to drive or operate machinery.

---

Q: Where is Vogalib approved for use internationally (e.g., in the US, UK, or only in France)?

The Vogalib brand name is recognized as approved in France. While the active ingredient, Metopimazine, is not approved by major regulatory bodies like the U.S. FDA or the European Medicines Agency (EMA), it is approved and available in several other countries under different national regulatory authorities.

How to Store and Dispose of Vogalib (Metopimazine)

Storage Requirements

Vogalib must be stored out of the sight and reach of children as a mandatory safety requirement for all medications. The official regulatory documents require the medicine to be stored at a temperature that does not exceed 30°C.

To maintain product stability, the orodispersible tablets must be protected from both light and moisture. This protection is ensured by keeping the medicine in the original outer package and the sealed, paper-coated aluminium sachet until the moment of use. The product must not be used after the expiration date printed on the packaging.

Disposal Instructions

Expired or unused Vogalib must not be disposed of in household waste or wastewater (e.g., flushed down a toilet or sink). Disposal must follow strict pharmaceutical waste management procedures: the product must be returned to a pharmacy or a designated official collection point.